Literature DB >> 2687688

Dexamethasone in the treatment of acute mountain sickness.

B D Levine1, K Yoshimura, T Kobayashi, M Fukushima, T Shibamoto, G Ueda.   

Abstract

Cerebral edema occurs in fatal cases of acute mountain sickness. Dexamethasone, commonly used to treat cerebral edema due to other causes, also reduces the symptoms of acute mountain sickness when given prophylactically. However, the efficacy of dexamethasone in the treatment of established acute mountain sickness remains uncertain. To investigate this question, we exposed six men in a hypobaric chamber to a simulated altitude of 3700 m (barometric pressure, 64 kPa [481 mm Hg]) for 48 hours on two occasions. Acute mountain sickness was diagnosed with use of a symptoms questionnaire, and dexamethasone (4 mg every six hours) or placebo was then given in a randomized, double-blind, crossover fashion. Dexamethasone reduced the symptoms of acute mountain sickness by 63 percent (P less than 0.05), whereas placebo had a minimal effect (reduction by 23 percent; P not significant). In spite of this response, one subject had mild cerebral edema on brain CT after both placebo and dexamethasone. Dexamethasone had no effect on fluid shifts, oxygenation, sleep apnea, urinary catecholamine levels, the appearance of chest radiographs or perfusion scans, serum electrolyte levels, hematologic profiles, or the results of psychometric tests. Dexamethasone treatment was complicated by mild hyperglycemia in all subjects (mean [+/- SE] glucose level, 7.3 +/- 1.3 mmol per liter [132 +/- 23 mg per deciliter]). We conclude that dexamethasone effectively reduces the symptoms of acute mountain sickness. However, it did not improve objective physiologic abnormalities related to exposure to high altitudes. We therefore recommend that dexamethasone be used only when descent is impossible, or to facilitate cooperation in evacuation efforts.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2687688     DOI: 10.1056/NEJM198912213212504

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  21 in total

1.  Prevention and Treatment of High-altitude Illness in Travelers.

Authors:  David R. Murdoch
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

2.  Acute pulmonary oedema on the Ruwenzori mountain range.

Authors:  R Naeije; C Mélot
Journal:  Br Heart J       Date:  1990-12

Review 3.  Acute mountain sickness. Effects and implications for exercise at intermediate altitudes.

Authors:  E C Pigman
Journal:  Sports Med       Date:  1991-08       Impact factor: 11.136

4.  Cerebral diffusion and T(2): MRI predictors of acute mountain sickness during sustained high-altitude hypoxia.

Authors:  John S Hunt; Rebecca J Theilmann; Zachary M Smith; Miriam Scadeng; David J Dubowitz
Journal:  J Cereb Blood Flow Metab       Date:  2012-12-05       Impact factor: 6.200

5.  Acute high-altitude illness: a clinically orientated review.

Authors:  Tom Smedley; Michael Pw Grocott
Journal:  Br J Pain       Date:  2013-05

Review 6.  Doctor on a mountaineering expedition.

Authors:  C H A'Court; R H Stables; S Travis
Journal:  BMJ       Date:  1995-05-13

Review 7.  Effects of altitude on mood, behaviour and cognitive functioning. A review.

Authors:  M S Bahrke; B Shukitt-Hale
Journal:  Sports Med       Date:  1993-08       Impact factor: 11.136

Review 8.  Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs.

Authors:  Víctor H Nieto Estrada; Daniel Molano Franco; Roger David Medina; Alejandro G Gonzalez Garay; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2017-06-27

9.  Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier.

Authors:  A J Ellsworth; E F Meyer; E B Larson
Journal:  West J Med       Date:  1991-03

10.  Ophthalmodynamometry for ICP prediction and pilot test on Mt. Everest.

Authors:  Henry W Querfurth; Philip Lieberman; Steve Arms; Steve Mundell; Michael Bennett; Craig van Horne
Journal:  BMC Neurol       Date:  2010-11-01       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.